<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891629</url>
  </required_header>
  <id_info>
    <org_study_id>EFAC-01</org_study_id>
    <nct_id>NCT02891629</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of the EyeControl Device</brief_title>
  <official_title>Safety and Feasibility of the EyeControl Device (Eye-based Communication Device) for ALS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyefree Assisting Communication Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyefree Assisting Communication Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EyeControl device is an eye movement-based communication device in the form of wearable
      glasses with connected infrared cam-era that tracks the pupil and translates blinks and
      movements into commands.This study is aimed to demonstrate the safety and feasibility of the
      EyeControl device in healthy volunteers, and ALS patients in early stages.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">January 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility - Successful Performance Rate of Device Features</measure>
    <time_frame>2 weeks</time_frame>
    <description>Ability to successfully perform at least 70% of device features (controlling the application and Free text features)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment - Number of Device Related Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>number of device related adverse events reported during the use of the device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>ALS (Amyotrophic Lateral Sclerosis)</condition>
  <arm_group>
    <arm_group_label>Device use in Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 healthy volunteers will be recruited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device use in ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 ALS patients in early stages will be recruited</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EyeControl device</intervention_name>
    <description>Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
    <arm_group_label>Device use in ALS patients</arm_group_label>
    <arm_group_label>Device use in Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects 18 to 65 years old

          2. Subject with understandable speaking communication

          3. Subject fluent in Hebrew (speech and writing skills)

             Additional inclusion criteria for Stage 2 of the study:

          4. Subjects with early stage ALS diagnosis - whose speech capability is unaffected

        Exclusion Criteria:

          1. Subjects with glasses or contact lenses

          2. Subjects with eye conditions such as Ptosis, Strabismus And Crossed Eyes

          3. Medical history of epilepsy

          4. Subjects who according to investigator's judgement, unable to comply with the
             requirements of this protocol

          5. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02891629/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Investigator decided to terminate subject participation due to the discovery of cataract during the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Device Use in Healthy Volunteers</title>
          <description>10 healthy volunteers will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
        <group group_id="P2">
          <title>Device Use in ALS Patients</title>
          <description>5 ALS patients in early stages will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device Use in Healthy Volunteers</title>
          <description>10 healthy volunteers will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
        <group group_id="B2">
          <title>Device Use in ALS Patients</title>
          <description>5 ALS patients in early stages will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="9.83"/>
                    <measurement group_id="B2" value="46.25" spread="5.26"/>
                    <measurement group_id="B3" value="36.6" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility - Successful Performance Rate of Device Features</title>
        <description>Ability to successfully perform at least 70% of device features (controlling the application and Free text features)</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Device Use in Healthy Volunteers</title>
            <description>10 healthy volunteers will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
          </group>
          <group group_id="O2">
            <title>Device Use in ALS Patients</title>
            <description>5 ALS patients in early stages will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility - Successful Performance Rate of Device Features</title>
          <description>Ability to successfully perform at least 70% of device features (controlling the application and Free text features)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.3"/>
                    <measurement group_id="O2" value="7.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment - Number of Device Related Adverse Events</title>
        <description>number of device related adverse events reported during the use of the device</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Device Use in Healthy Volunteers</title>
            <description>10 healthy volunteers will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
          </group>
          <group group_id="O2">
            <title>Device Use in ALS Patients</title>
            <description>5 ALS patients in early stages will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment - Number of Device Related Adverse Events</title>
          <description>number of device related adverse events reported during the use of the device</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events data was collected only during the trial, meaning during the 4 sessions, of about 2.5-3 hours, for each participant, performed over 2 weeksâ€™ time.</time_frame>
      <desc>An AE can be any unintended sign, symptom, disease or injury or any untoward clinical signs (including an abnormal laboratory findings) in subjects, users or other persons whether or not related to the investigational medical device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Device Use in Healthy Volunteers</title>
          <description>10 healthy volunteers will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
        <group group_id="E2">
          <title>Device Use in ALS Patients</title>
          <description>5 ALS patients in early stages will be recruited
EyeControl device: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <description>Participant complained on dry eyes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye Fatigue</sub_title>
                <description>Participant complained on eye fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Or Retzkin, CEO</name_or_title>
      <organization>EyeFree Assisting Communication</organization>
      <phone>+972526490093</phone>
      <email>or@eyecontrol.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

